General Information of the Compound
| Compound ID |
CP0946590
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
(S)-(-)-4-[2,5-Dioxo-4-(hydroxymethyl)-3-methyl-4-phenylimidazolidin-1-yl]-2-(trifluoromethyl)benzonitrile
Show/Hide
|
||||||||||||||||||
| Synonyms |
G-100192
GLPG-0492
SARMs (osteoporosis), ProSkelia
SARMs (osteoporosis), ProStraken
SARMs (osteoporosis/cachexia), Galapagos
Selective androgen receptor modulators, Galapagos
Selective androgen receptor modulators, ProSkelia
Selective androgen receptor modulators, ProStrakan
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C19H14F3N3O3
|
||||||||||||||||||
| Molecular Weight |
389.333
|
||||||||||||||||||
| Canonical SMILES |
CN1C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)[C@@]1(CO)c1ccccc1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C19H14F3N3O3/c1-24-17(28)25(14-8-7-12(10-23)15(9-14)19(20,21)22)16(27)18(24,11-26)13-5-3-2-4-6-13/h2-9,26H,11H2,1H3/t18-/m1/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
VAJGULUVTFDTAS-GOSISDBHSA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Clinical Information about the Compound